Basis: (FMP quote price / unrounded diluted TTM EPS) / explicitly dated EPS growth percent. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-09-15T14:45:31.786Z.
Calculation as of: 2026-09-15T14:45:31.786Z.
Quote observation: 2026-09-15T14:45:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4d0dd03ce25408bf7ac658d648b2d5a2e9572817b3796d023b4e65a6fbfd6d64
PEG RATIO
N/A
Boston Scientific Corporation
Market Cap
$65.30B
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Boston Scientific Corporation (BSX) | $65.30B | N/A |
| Cencora, Inc. (COR)vs › | $62.86B | N/A |
| Moderna, Inc. (MRNA)vs › | $56.82B | N/A |
| Cardinal Health, Inc. (CAH)vs › | $54.75B | N/A |
| Cigna Corporation (CI)vs › | $76.30B | N/A |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $80.11B | N/A |
| Becton, Dickinson and Company (BDX)vs › | $50.37B | N/A |
| Edwards Lifesciences Corporation (EW)vs › | $49.18B | N/A |
| Humana Inc. (HUM)vs › | $47.79B | N/A |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $44.72B | N/A |
PEG Ratio
N/A
P/E Ratio
17.9
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute